This site is intended for Healthcare Professionals only

You’re doing great.  (0% complete)

quiz close icon

module menu icon Diuretics

Diuretics

For a heart failure patient, fluid congestion may be any or all of the following:

  1. Peripheral oedema – build-up of fluid from the feet upwards. The patient may notice that their shoes are tighter, there are marks on the legs by the top of the socks, there is general swelling/tightness of the skin and/or pitting oedema (leaving a thumbprint after pressing)
  2. Abdominal bloating – with discomfort, loss of appetite and symptoms of breathlessness when bending over (e.g. tying shoelaces, gardening)
  3. Pulmonary oedema (fluid on the lungs) with increasing symptoms of shortness of breath, cough, difficulty lying flat in bed or waking due to breathlessness, sleeping with extra pillows or more propped up in the bed, or even sleeping in a chair.

The aim is to gradually remove the accumulated fluid – no more than 1-2kg/day – as more rapid diuresis can lead to acute kidney injury (AKI). It is helpful if the patient can self-monitor by both reporting on symptoms and by measuring their weight each morning. The rationale for measuring weight is to assess change in congestion with the weight decreasing as fluid is removed or, conversely, still increasing if treatment is not effective. 

A pharmacist explaining to the patient that they are not, in this instance, interested in their weight per se often relieves anxiety over recording and reporting the weight. In some cases, sensitive questioning regarding adherence may be required as patients often cite diuretic use as disruptive to their daily schedule and may omit doses that are ‘inconvenient’, leading to treatment failure. 

Table 2: Licensed indications for common medications recommended for treating heart failure

Class of medicine

HFrEF

HFpEF and HFmrEF

Diuretics

Loop diuretic (e.g. furosemide, bumetanide)

Thiazide diuretic (e.g. bendroflumethiazide,
metolazone)

√  
if required
for congestion

√  
if required for congestion

Angiotensin converting enzyme inhibitor (ACEi)

(e.g. ramipril, enalapril)


prognostic benefit

if for co-morbidity

Angiotensin receptor blocker (ARB)

(e.g. candesartan, losartan)

Alternative to ACEi if intolerance (e.g. cough)


prognostic benefit

if for co-morbidity

Angiotensin receptor neprilysin inhibitor (ARNi)

sacubitril + valsartan (Entresto)

Instead of ACEi or any other ARB on specialist recommendation


prognostic benefit

not approved by NICE for HFpEF or HFmrEF

Beta-blocker licensed for heart failure

bisoprolol, carvedilol, nebivolol


prognostic benefit

if for co-morbidity

Mineralocorticoid receptor antagonist (MRA)

spironolactone or eplerenone


prognostic benefit

if for co-morbidity

SGLT2 inhibitor for heart failure
dapagliflozin or empagliflozin

(Updated NICE guidance on empagliflozin expected in November 2023)


prognostic benefit

NICE recommended dapagliflozin (May 2023) for use in HF with mildly reduced or preserved ejection fraction